Nasus PharmaNSRX
13F holders, Q4 2025 (December 31)2holders
0new positions
0sold out
$9.15avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Nasus Pharma Ltd. (NSRX) in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were Morgan Stanley ($18K) and UBS Group AG ($3K).
- Company
- Nasus Pharma Ltd.
- CUSIP
- M7071P109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q4 2025: 863 shares sold, net −863 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Morgan Stanley | 0.00% | No change | 2,000 | $18K |
| UBS Group AG | 0.00% | Reduce -69.5% | 378 | $3K |
"% of holder's portfolio" is NSRX's weight in each manager's 13F, not the share of Nasus Pharma Ltd. the manager owns.